Who Supplies Gliclazide to India from GERMANY

Importing finished pharmaceutical formulations containing Gliclazide into India requires compliance with the Central Drugs Standard Control Organisation (CDSCO) regulations. The importing company must obtain a valid Drug Import License from the Directorate General of Foreign Trade (DGFT). Additionally, the product must be registered with CDSCO, which involves submitting Form 40/41 along with necessary documents such as the Certificate of Pharmaceutical Product (CoPP), Good Manufacturing Practice (GMP) certificate, and stability data. The registration process typically takes 6 to 12 months, depending on the completeness of the application and the regulatory workload. For formulations under HS Code 30049099, specific requirements include providing a Certificate of Analysis (CoA) and ensuring the product meets the standards set by the Indian Pharmacopoeia. The importing company must also ensure that the product complies with the Drugs and Cosmetics Act, 1940, and the rules thereunder.

Upon arrival in India, each batch of Gliclazide formulations must undergo quality testing at a CDSCO-approved laboratory. The batch-wise testing includes verification of the Certificate of Analysis (CoA), assessment of stability data (preferably in ICH Zone IV conditions), and confirmation that the product meets the standards of the Indian Pharmacopoeia. Port inspection by customs drug inspectors is mandatory to ensure compliance with Indian regulations. If a batch fails to meet the required standards, it may be subject to rejection, re-exportation, or destruction, as determined by the authorities.

Between 2024 and 2026, the CDSCO has implemented several regulatory updates affecting the import of finished pharmaceutical formulations. The introduction of the Production Linked Incentive (PLI) scheme has incentivized domestic manufacturing, potentially impacting the volume of imports. Additionally, bilateral agreements between India and Germany have facilitated smoother trade relations, including mutual recognition of Good Manufacturing Practices (GMP), which may streamline the import process for German manufacturers. These developments aim to balance the promotion of domestic industry with the need for high-quality imported pharmaceuticals.

India imports finished Gliclazide formulations primarily due to the demand for patented or branded products, specialized dosage forms, and formulations not manufactured domestically. The domestic capacity to produce certain Gliclazide formulations is limited, leading to reliance on imports to meet patient needs. The market size for Gliclazide formulations in India is substantial, with a total export market of $300.8 million across 238 exporters to 109 countries, indicating a significant demand both domestically and internationally.

The Basic Customs Duty (BCD) for finished pharmaceutical formulations under HS Code 30049099 is 10%. An Integrated Goods and Services Tax (IGST) of 12% is applicable on the CIF value. Additionally, a Social Welfare Surcharge (SWS) of 10% is levied on the BCD. There are no specific exemptions or concessional duties for imports from Germany under this HS code. The total landed duty, combining BCD, SWS, and IGST, is approximately 23.536% of the CIF value.

India sources finished Gliclazide formulations from Germany due to the country's competitive advantages, including the availability of patented formulations, specialized dosage forms, and high-quality manufacturing standards. German manufacturers often provide formulations that are not produced domestically, fulfilling specific market needs. While other countries like China, the United States, and other European nations also supply Gliclazide formulations, Germany's reputation for quality and innovation positions it favorably in the Indian market.

India imports finished Gliclazide formulations from Germany due to the availability of patented formulations, specialized dosage forms, and high-quality manufacturing standards. German manufacturers often provide formulations that are not produced domestically, fulfilling specific market needs. The demand for such specialized products in India necessitates sourcing from countries with advanced pharmaceutical manufacturing capabilities like Germany.

When compared to other potential sources like China, the United States, and other European countries, Germany offers a competitive advantage in terms of product quality, regulatory compliance, and reliability. German pharmaceutical products are known for their adherence to stringent quality standards and innovative formulations, making them a preferred choice for Indian importers seeking high-quality Gliclazide formulations.

Indian importers face several risks when sourcing finished Gliclazide formulations from Germany, including single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. To mitigate these risks, importers should consider diversifying their supplier base, closely monitoring currency exchange rates, staying updated on regulatory changes, and establishing robust quality assurance processes. While there have been no significant shortages reported in recent years, maintaining a proactive approach to supply chain management is essential.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source and mitigate supply chain risks.
2. 2Inventory Planning: Maintain optimal inventory levels to buffer against potential supply disruptions.
3. 3Payment Terms: Negotiate favorable payment terms, such as Letters of Credit (LC), Documents Against Payment (DA), or Documents Against Acceptance (DP), to manage financial exposure.
4. 4Minimum Order Quantities (MOQs): Clarify MOQs with suppliers to ensure alignment with demand forecasts and inventory management.
5. 5Supplier Qualification: Conduct thorough due diligence on suppliers, including audits and assessments of their manufacturing facilities, quality control processes, and compliance with international standards.

1. DGFT Import License: